Stay updated on Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:07:32.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the evaluation of pembrolizumab in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:11.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying conditions such as relapsed or refractory classical Hodgkin Lymphoma and other health requirements. Previously, this section had no information provided.
    Difference
    45%
    Check dated 2024-05-22T21:10:11.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:31:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Brentuximab in Hodgkin Lymphoma Clinical Trial page.